Guardant Health/$GH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
- Ticker
- $GH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,498
- Headquarters
- Palo Alto, United States
- Website
- guardanthealth.com
Guardant Health Metrics
BasicAdvanced
$24B
-
-$3.50
1.58
-
Price and volume
Market cap
$24B
Beta
1.58
52-week high
$191.05
52-week low
$74.55
Average daily volume
1.8M
Financial strength
Current ratio
4.026
Quick ratio
3.533
Long term debt to equity
-7.49
Total debt to equity
-7.49
Interest coverage (TTM)
-97.64%
Profitability
EBITDA (TTM)
-430.571
Gross margin (TTM)
65.01%
Net profit margin (TTM)
-38.33%
Operating margin (TTM)
-39.64%
Effective tax rate (TTM)
0.23%
Revenue per employee (TTM)
$470,000
Management effectiveness
Return on assets (TTM)
-18.07%
Return on equity (TTM)
171.64%
Valuation
Price to revenue (TTM)
19.558
Price to book
-107.19
Price to tangible book (TTM)
-73.42
Price to free cash flow (TTM)
-96.124
Free cash flow yield (TTM)
-1.04%
Free cash flow per share (TTM)
-1.86
Growth
Revenue change (TTM)
42.74%
Earnings per share change (TTM)
4.74%
3-year revenue growth (CAGR)
32.36%
3-year earnings per share growth (CAGR)
-10.47%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Analyst projections of the future price of Guardant Health stock.
Bulls say / Bears say
Shield adoption is accelerating: second-quarter screening revenue rose to $52.9 million from $14.8 million a year earlier, and Guardant raised its 2026 screening outlook. New insurer policies, including EviCore’s, expand access to about 94 million eligible people. (Guardant Health, Guardant Health)
Oncology testing provides a second growth engine: test volume increased 63% year on year in the second quarter, while oncology revenue rose 38%. FDA approval of the expanded Guardant360 Liquid CDx could further support adoption of the company’s profiling tests. (Guardant Health)
Shield’s unit economics may improve as volume scales: management said the newly approved workflow is expected to reduce the test’s cost by about 15% by the end of 2026. Lower costs could improve margins as screening volumes grow, although the savings are not yet fully realised. (The Motley Fool)
Growth is not yet translating into lower losses: second-quarter net loss widened to $120.1 million from $99.9 million a year earlier, and Guardant expects $195 million to $205 million of free-cash-flow burn in 2026. Continued commercial and lab investment makes a timely path to profitability an execution risk. (Guardant Health)
A patent dispute creates a material liability risk: a court upheld the infringement verdict and awarded an ongoing 6% royalty, while Guardant estimates possible losses of up to $250 million through June 2026. The company plans to appeal, so the final cost remains uncertain. (SEC)
Shield detects colorectal cancers but is much less effective at finding advanced precancerous lesions, which are important to prevent cancers before they develop. The American Cancer Society’s review reports 13.2% sensitivity for these lesions in the ECLIPSE study, a limitation that may make some clinicians favour other screening options. (CA: A Cancer Journal for Clinicians)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Guardant Health News
AllArticlesVideos
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga1 week ago
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
MarketBeat2 weeks ago
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Business Wire3 weeks ago
Funds containing Guardant Health
AllUSDEURGBP
Fund name | Fund size | $GH weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.63% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.63% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.63% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.58% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.58% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.